高磷酸鹽血症治療市場：策略性洞察與預測（2026-2031 年）

高磷酸鹽血症治療市場預計將以 4.44% 的複合年成長率成長，從 2025 年的 21.13 億美元成長到 2031 年的 27.43 億美元。

受全球透析患者數量不斷成長、強調個體化礦物質管理的臨床指南不斷完善以及慢性腎臟病（ CDI）患病率上升等因素的推動，高磷酸鹽血症治療市場正經歷著顯著的變革。這項市場變革的特點在於，人們逐漸認知到有效的磷管理，特別是使用非鈣磷酸鹽粘合劑，對於降低透析患者的長期心血管風險和改善治療效果至關重要。臨床證據、法律規範和以患者為中心的護理模式的融合，正促使醫院腎內科、透析中心和門診腎臟診所廣泛採用差異化療法。腎臟科醫師在評估療法時，不僅關注其降低磷水平的療效，還日益關注用藥負擔、胃腸道耐受性、遵守用藥性以及心血管安全性。改善全球腎臟病預後組織（KDIGO）發布的慢性腎臟病、礦物質和骨骼疾病（CKD-MBD）臨床實踐指南建議採用個人化的磷管理方法，透過連續的生化檢測，減少對單一實驗室閾值的依賴，並鼓勵以患者為中心的治療選擇。隨著市場對新型作用機制、可減輕用藥負擔的製劑以及真實世界數據（REW）的大量投資，高磷酸鹽血症慢性腎臟病診療路徑中的關鍵支柱。

市場促進因素

• 全球透析患者數量的不斷成長是高磷酸鹽血症治療市場的主要驅動力。由於透析患者腎臟清除磷的能力有限，藥物控制磷水平已成為疾病管理的常規組成部分。根據美國腎臟數據系統（USRDS）統計，美國有超過55萬名患者正在接受維持性透析治療，而歐洲和亞洲的國家腎臟登記數據顯示，由於人口老化和糖尿病盛行率上升，透析計畫也不斷擴展。由於磷酸鹽粘合劑在整個透析治療期間都需要服用，因此生產商受益於持續的需求，而非一次性的治療性介入。大規模透析服務提供者正在加強綜合腎臟護理服務，將實驗室監測、營養指導和藥物管理相結合，從而提高治療依從性並維持穩定的處方量。
• 越來越多的臨床指引推薦支持個人化磷管理，這透過拓展治療選擇進一步加速了市場成長。近期腎臟病指引更強調預防與持續性磷失衡相關的長期併發症，而非僅僅追求嚴格的生化指標。 KDIGO CKD-MBD 指引建議在調整治療方案前，評估磷水平變化趨勢以及血清鈣和副甲狀腺素。這鼓勵醫生根據個人化的心血管風險、胃腸道耐受性和用藥依從性來選擇治療方案，而不是僅依賴實驗室閾值。個人化治療策略透過增加非鈣磷酸鹽粘合劑在血管鈣化和復發性高鈣血症患者的應用，擴大了適用人群。
• 糖尿病和高血壓盛行率的不斷上升擴大了高風險族群，並導致對藥物的長期需求持續存在。世界衛生組織（WHO）和國際糖尿病聯盟（IDF）指出，糖尿病在已開發經濟體和新興經濟體的盛行率均持續上升，而高血壓控制不佳仍是導致腎功能進行性性損害的主要原因。隨著越來越多的患者發展到慢性腎臟病（CKD）晚期，腎臟科醫生發現需要進行磷監測和治療性介入的患者數量也在增加。透過篩檢早期發現CKD提高了腎臟專科轉診率，使臨床醫生能夠在出現嚴重代謝併發症之前實施飲食指導、實驗室後續觀察和降磷治療。
• 差異化降磷療法的研發正在拓展醫師的治療選擇，並提高病患的依從性。市場創新正從單純提高磷結合能力轉向改善患者依從性並減輕治療負擔。各公司正投資研發旨在減輕用藥負擔、提高胃腸道耐受性以及提供新型降磷作用機制的療法。近期監管部門的批准和不斷擴大的臨床證據加劇了製造商之間的競爭，促使他們在患者便利性、安全性以及與現有慢性腎臟病（CKD）療法的聯合治療方面打造差異化產品。製劑和作用機制的創新預計將繼續成為影響處方決策的關鍵因素。

市場限制因素

• 治療負擔是影響透析患者長期用藥順從性並限制治療效果的因素之一。在磷酸鹽粘合劑治療中，患者通常需要在每餐和加餐時服用多片藥片，這使其成為慢性腎臟病（CKD）管理中最繁重的環節之一。接受維持性透析的患者除了服用磷酸鹽粘合劑外，通常還需要服用治療貧血、礦物質和骨骼疾病、高血壓、糖尿病和心血管疾病的藥物。這種累積的治療負擔會導致漏服藥物和磷酸鹽管理不穩定。在以治療連續性為關鍵處方標準的市場中，能夠簡化給藥方式或改善胃腸道耐受性的產品有望獲得競爭優勢。
• 產品成本和報銷政策會影響治療選擇，並限制患者獲得更高價格的替代療法。雖然非鈣基磷酸鹽粘合劑被廣泛推薦用於某些特定患者群體，但其購買成本仍高於傳統的鈣基產品。公共醫療報銷機構和私人保險公司通常會透過醫療技術評估、處方藥清單審查和預算影響分析來評估磷酸鹽粘合劑，然後再確定其合格報銷資格。採用固定收費模式的醫院和透析服務提供者可能會優先考慮對無鈣暴露禁忌症的患者使用低成本的治療方案。對於價格較高的產品，除了降低磷酸鹽水平外，還需要有證據支持其臨床價值，例如降低住院率、提高遵守用藥或降低心血管風險。
• 關於最佳磷目標值的臨床不確定性影響處方模式，並阻礙了高成本治療方案的統一應用。儘管人們普遍認為持續性高磷酸鹽血症會導致不良臨床結局，但日本腎臟病學會承認，在許多患者群體中，支持精確血清磷目標值的證據仍然有限。 KDIGO CKD-MBD指南建議根據磷水平的進行性或持續性升高進行治療，而不是嚴格的數值標準。醫生對指引建議的不同解讀會影響處方強度、藥物選擇和治療持續時間，這可能導致不同醫療系統之間處方模式的差異。
• 口服磷酸鹽粘合劑的消化器官系統副作用仍然是一個持續存在的挑戰，也是導致治療中斷的主要原因。由於大多數磷酸鹽粘合劑作用於胃腸道，消化器官系統副作用是導致治療中斷和遵守用藥差的最常見原因之一。便秘、噁心、腹部不適和腹脹是多種磷酸鹽結合劑療法常見的副作用。儘管製藥公司已透過改進製劑、調整劑量建議以及持續進行其他降磷機制的臨床評估來解決這些問題，但消化器官系統耐受性仍然是腎臟科醫生選擇藥物時的一個重要考慮因素。
• 供應鏈韌性和原料供應影響著藥品級產品的生產連續性。磷酸鹽粘合劑需要藥用級活性成分、專門的生產流程和持續的品管才能符合監管標準。近年來，全球製藥公司為因應供應鏈中斷，增加了供應鏈多元化力度，尤其針對那些依賴地理位置集中的原料來源或契約製造組織（CMO）的產品。製造商不斷加強區域生產網路並實現供應商多元化，以降低運輸中斷、地緣政治不確定性和貿易政策變化帶來的風險。

目錄

第1章執行摘要

第2章：市場概述

• 市場概覽
• 市場的定義
• 調查範圍
• 市場區隔

第3章：商業趨勢

• 市場促進因素
• 市場限制因素
• 市場機遇
• 波特五力分析
• 產業價值鏈分析
• 政策與法規
• 策略建議

第4章 技術展望

第5章高磷酸鹽血症治療市場：依產品分類

• 塞維拉姆
• 鈣基磷酸鹽粘合劑
• 鐵基粘合劑
• 碳酸燈籠
• 其他

第6章：高磷酸鹽血症治療市場：依檢測類型分類

• 血清磷檢測
• 血清鈣濃度檢測
• 血中尿素氮（BUN）檢測
• 血清肌酸酐檢測
• 其他

第7章：高磷酸鹽血症治療市場：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

第8章高磷酸鹽血症治療市場：按地區分類

• 北美洲
  • 依產品
  • 按測試類型
  • 透過分銷管道
  • 國家
    • 美國
    • 加拿大
    • 墨西哥
• 南美洲
  • 依產品
  • 按測試類型
  • 透過分銷管道
  • 國家
    • 巴西
    • 阿根廷
    • 其他
• 歐洲
  • 依產品
  • 按測試類型
  • 透過分銷管道
  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
• 中東和非洲
  • 依產品
  • 按測試類型
  • 透過分銷管道
  • 國家
    • 沙烏地阿拉伯
    • UAE
    • 其他
• 亞太地區
  • 依產品
  • 按測試類型
  • 透過分銷管道
  • 國家
    • 中國
    • 日本
    • 印度
    • 韓國
    • 台灣
    • 其他

第9章：競爭環境與分析

• 主要公司及策略分析
• 市佔率分析
• 合併、收購、協議和合作關係
• 競爭環境儀錶板

第10章：公司簡介

• Ardelyx, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co., Ltd.
• Sanofi SA
• Akebia Therapeutics, Inc.
• Fresenius Medical Care AG & Co. KGaA
• Vifor Pharma AG

第11章附錄

The Hyperphosphatemia Treatment Market, with a 4.44% CAGR, is forecasted to rise from USD 2.113 billion in 2025 to USD 2.743 billion in 2031.

The hyperphosphatemia treatment market is undergoing significant transformation driven by the expanding global dialysis population, evolving clinical guidelines emphasizing individualized mineral management, and the growing prevalence of chronic kidney disease. The market's evolution is characterized by the recognition that effective phosphate control, particularly through non-calcium phosphate binders, is essential for reducing long-term cardiovascular risk and improving outcomes in dialysis patients. The convergence of clinical evidence, regulatory frameworks, and patient-centered care models is enabling broader adoption of differentiated therapies across hospital nephrology departments, dialysis organizations, and outpatient renal clinics. Nephrologists increasingly evaluate therapies based on pill burden, gastrointestinal tolerability, adherence potential, and cardiovascular safety rather than phosphate-lowering efficacy alone. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) recommends individualized phosphate management using serial biochemical assessment, reducing reliance on single laboratory thresholds and encouraging tailored therapy selection. The market is witnessing significant investment in novel mechanisms of action, reduced pill burden formulations, and real-world evidence generation, positioning hyperphosphatemia management as a cornerstone within broader chronic kidney disease care pathways.

Market Drivers

• The expansion of the global dialysis population represents the primary driver for the hyperphosphatemia treatment market. Dialysis patients have limited renal phosphate clearance, making pharmacological phosphate control a routine component of disease management. The U.S. Renal Data System reports more than 550,000 patients receiving maintenance dialysis in the United States, while national renal registries across Europe and Asia indicate expanding dialysis programs driven by aging populations and increasing diabetes prevalence. Since phosphate binders are prescribed throughout the duration of dialysis treatment, manufacturers benefit from recurring demand rather than one-time therapeutic intervention. Large dialysis providers are strengthening integrated renal care services that combine laboratory monitoring, nutritional counseling, and medication management, improving treatment adherence and supporting consistent prescribing volumes.
• Clinical guideline recommendations increasingly supporting individualized phosphate management further accelerate market growth through expanded therapeutic options. Recent nephrology guidelines place greater emphasis on preventing long-term complications associated with persistent phosphate imbalance than on achieving rigid biochemical targets. The KDIGO CKD-MBD guideline recommends evaluating phosphate trends alongside serum calcium and parathyroid hormone before adjusting therapy. This has encouraged physicians to select treatments based on patient-specific cardiovascular risk, gastrointestinal tolerance, and adherence potential rather than relying solely on laboratory thresholds. Individualized treatment strategies encourage broader use of non-calcium phosphate binders among patients with vascular calcification or recurrent hypercalcemia, expanding the addressable patient population.
• The increasing prevalence of diabetes and hypertension is enlarging the at-risk patient population and sustaining long-term pharmaceutical demand. According to the World Health Organization and the International Diabetes Federation, diabetes prevalence continues to rise across both developed and emerging economies, while uncontrolled hypertension remains a major contributor to progressive renal impairment. As larger numbers of patients advance toward later CKD stages, nephrology services are managing increasing volumes of individuals who require phosphate monitoring and therapeutic intervention. Earlier identification of CKD through screening initiatives has improved referral rates to specialist nephrology care, allowing clinicians to implement dietary counseling, laboratory surveillance, and phosphate-lowering therapy before severe metabolic complications develop.
• The development of differentiated phosphate-lowering therapies is expanding physician treatment options and improving patient adherence. Product innovation within the market has shifted toward improving adherence and reducing treatment burden rather than solely increasing phosphate-binding capacity. Companies have invested in therapies designed to reduce pill burden, improve gastrointestinal tolerability, and offer alternative mechanisms of phosphate reduction. Recent regulatory approvals and expanded clinical evidence have strengthened competition among manufacturers seeking to differentiate products through patient convenience, safety, and complementary use alongside established CKD therapies, with innovation in formulation and mechanism of action expected to remain an important factor influencing prescribing decisions.

Market Restraints

• High treatment burden reduces long-term adherence among dialysis patients and constrains therapeutic effectiveness. Phosphate binder therapy often requires patients to take multiple tablets with every meal and snack, making it one of the highest pill-burden components of chronic kidney disease management. Patients receiving maintenance dialysis frequently take medications for anemia, mineral and bone disorders, hypertension, diabetes, and cardiovascular disease in addition to phosphate binders. This cumulative treatment burden contributes to missed doses and inconsistent phosphate control. Products that simplify dosing or improve gastrointestinal tolerability may gain an advantage in markets where treatment persistence has become an important prescribing consideration.
• Product cost and reimbursement policies influence therapy selection and limit access to premium-priced alternatives. Although non-calcium phosphate binders are widely recommended for selected patient populations, their acquisition cost remains higher than that of conventional calcium-based products. Public reimbursement agencies and private insurers frequently evaluate phosphate binders through health technology assessments, formulary reviews, and budget impact analyses before determining reimbursement eligibility. Hospitals and dialysis providers operating under fixed reimbursement models may prioritize lower-cost therapies for patients without contraindications to calcium exposure. Premium-priced products require evidence demonstrating clinical value beyond phosphate reduction, including reduced hospitalization, improved adherence, or lower cardiovascular risk.
• Clinical uncertainty regarding optimal phosphate targets affects prescribing patterns and limits uniform adoption of higher-cost therapeutic options. Despite broad agreement that persistent hyperphosphatemia contributes to adverse clinical outcomes, nephrology societies acknowledge that evidence supporting precise serum phosphate targets remains limited for many patient groups. The KDIGO CKD-MBD guideline recommends treatment based on progressively or persistently elevated phosphate concentrations rather than strict numerical thresholds. Variability in physician interpretation of guideline recommendations can influence prescribing intensity, product selection, and treatment duration, creating heterogeneous prescribing patterns across healthcare systems.
• Gastrointestinal adverse effects remain a persistent limitation of oral phosphate binders and contribute to treatment discontinuation. Most phosphate binders act within the gastrointestinal tract, making digestive side effects one of the most common reasons for treatment discontinuation or reduced adherence. Constipation, nausea, abdominal discomfort, and bloating are frequently reported across several phosphate-binding therapies. Manufacturers have responded through formulation improvements, modified dosing recommendations, and continued clinical evaluation of alternative phosphate-lowering mechanisms, yet gastrointestinal tolerability remains an important purchasing criterion for nephrologists.
• Supply chain resilience and raw material availability affect manufacturing continuity for pharmaceutical-grade products. Phosphate binders require pharmaceutical-grade active ingredients, specialized manufacturing processes, and consistent quality control to meet regulatory standards. Global pharmaceutical companies have expanded supply chain diversification following disruptions experienced during recent years, particularly for products relying on geographically concentrated raw material sources or contract manufacturing organizations. Manufacturers continue to strengthen regional production networks and supplier diversification to reduce exposure to transportation disruptions, geopolitical uncertainty, and changing trade policies.

Technology and Product Insights

• The technology landscape is characterized by the growing importance of novel mechanisms of action, reduced pill burden formulations, and real-world evidence generation. The Sevelamer segment represents the most commercially important product category because it provides effective phosphate control without increasing systemic calcium exposure. Clinical practice guidelines increasingly support the use of non-calcium phosphate binders for patients at higher risk of vascular calcification or recurrent hypercalcemia. Multiple generic formulations have expanded market accessibility, while branded manufacturers continue to differentiate products through formulation improvements, clinical evidence, and physician education. Competition therefore extends beyond pricing to include treatment persistence, gastrointestinal tolerability, dosing convenience, and real-world clinical outcomes.
• The iron-based phosphate binders segment is receiving greater clinical attention for long-term management of vascular calcification risk. These products offer an alternative mechanism of phosphate reduction while simultaneously addressing iron deficiency, which is common among dialysis patients. The lanthanum carbonate segment provides effective phosphate binding without calcium exposure, though gastrointestinal tolerability and long-term safety monitoring remain important prescribing considerations.
• The Test Type segment analysis reveals that Serum Phosphate Level Tests represent the most essential diagnostic component, as regular monitoring guides treatment titration and disease management. Serum Calcium Level Tests, Blood Urea Nitrogen (BUN) Tests, and Serum Creatinine Tests are routinely performed alongside phosphate measurement to assess overall mineral metabolism and renal function. Continuous laboratory testing supports recurring demand for diagnostic monitoring alongside pharmacological treatment, with hospital-based nephrology care remaining the principal channel for initiating and monitoring therapy.
• The Distribution Channel analysis indicates that Hospital Pharmacies dominate the market due to the specialist nature of prescribing and the close integration between nephrology departments and hospital-based pharmacies. Retail Pharmacies serve patients on stable long-term therapy who require convenient medication access, while Online Pharmacies are emerging as a supplementary channel for patients managing multiple chronic medications, though regulatory restrictions on prescription fulfillment vary across jurisdictions.
• The integration of clinical evidence generation is becoming increasingly important as manufacturers complement regulatory approval with real-world studies, comparative effectiveness data, and health economic analyses to simplify adoption among nephrologists and healthcare systems operating across multiple regions. European demand is supported by comprehensive chronic kidney disease management within publicly funded healthcare systems and consistent implementation of nephrology guidelines. Countries including Germany, the United Kingdom, France, and Spain maintain established renal registries and structured dialysis services that facilitate routine phosphate monitoring throughout disease progression. Pricing negotiations and health technology assessments play a greater role in Europe than in many other regions, with competition frequently centering on cost-effectiveness, long-term safety, and evidence supporting reduced cardiovascular complications.

Competitive and Strategic Outlook

• The competitive landscape is characterized by a moderately concentrated structure in which a limited number of pharmaceutical companies supply branded therapies, while generic manufacturers intensify price competition for established phosphate binders. Ardelyx, Inc., Kissei Pharmaceutical Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Sanofi S.A., Akebia Therapeutics, Inc., Fresenius Medical Care AG & Co. KGaA, and Vifor Pharma AG compete through safety profile, pill burden, formulation, reimbursement support, and the strength of clinical evidence supporting long-term use. Competition extends beyond product efficacy because most approved binders achieve clinically meaningful phosphate reduction when used appropriately.
• Larger suppliers benefit from diversified nephrology portfolios that address interconnected complications such as anemia, mineral and bone disorders, and cardiovascular risk. This approach allows manufacturers to strengthen relationships with nephrologists and dialysis providers by offering complementary therapies across the CKD treatment pathway instead of competing within a single product category. Ardelyx has strengthened competition by commercializing tenapanor, a first-in-class phosphate absorption inhibitor that reduces intestinal phosphate uptake through a mechanism distinct from conventional phosphate binders. The company positions its product around reducing pill burden and improving treatment adherence, addressing recurring challenges reported by nephrologists. Commercial expansion has focused on payer engagement, physician education, and post-approval evidence generation to support broader adoption.
• Fresenius Medical Care occupies a distinctive position because it participates across several stages of the renal care value chain. In addition to operating one of the world's largest dialysis service networks, the company provides dialysis equipment, clinical services, and pharmaceutical products. This vertical integration offers direct insight into prescribing patterns, patient adherence, laboratory monitoring, and treatment outcomes, enabling closer alignment between product development and clinical practice than is available to companies focused solely on pharmaceutical manufacturing. Vifor Pharma, now operating within the CSL group, has maintained a strong nephrology focus through therapies addressing iron deficiency, kidney disease, and associated complications, combining product innovation, specialist physician engagement, and collaboration with dialysis organizations to strengthen its position.
• Recent key developments highlight the industry's focus on novel mechanisms, reduced pill burden, and commercial expansion. R1 Therapeutics launched with a US$77.5 million Series A financing and secured an exclusive license for AP306, an investigational oral hyperphosphatemia therapy designed to reduce pill burden for dialysis patients. Unicycive Therapeutics announced FDA acceptance of the resubmitted NDA for oxylanthanum carbonate following resolution of manufacturing issues, positioning the low-pill-burden phosphate binder for a potential 2026 commercial launch. The company presented new data demonstrating significant pill burden reduction while maintaining phosphate control. Ardelyx expanded commercialization efforts for XPHOZAH through physician education, patient access initiatives, and market expansion activities, supporting wider adoption of its first-in-class phosphate absorption inhibitor.
• Barriers to entry remain relatively high despite generic competition. New entrants must complete extensive clinical development, satisfy stringent regulatory requirements, establish manufacturing quality systems, and secure reimbursement within healthcare systems that increasingly require evidence of cost-effectiveness alongside clinical efficacy. Long-standing relationships between nephrologists, dialysis organizations, and established suppliers further increase switching costs, particularly where integrated care pathways and procurement contracts are already in place. Companies are strengthening regional manufacturing and distribution networks to improve delivery reliability and mitigate supply-chain disruptions while investing in real-world evidence and health economic studies to support reimbursement discussions.

Short Conclusion

• The hyperphosphatemia treatment market is positioned for sustained growth driven by the convergence of expanding dialysis populations, clinical guideline evolution, and product innovation addressing treatment burden. The transition from uniform biochemical targets toward individualized CKD-MBD management represents a fundamental shift in clinical practice. While challenges related to adherence, reimbursement, and gastrointestinal tolerability persist, strategic investments in differentiated mechanisms of action, patient-centered formulation, and real-world evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with phosphate management evolving into an increasingly integrated component within broader chronic kidney disease care pathways, supporting improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HYPERPHOSPHATEMIA TREATMENT MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Sevelamer
• 5.3. Calcium-based Phosphate Binders
• 5.4. Iron-based Phosphate Binders
• 5.5. Lanthanum Carbonate
• 5.6. Others

6. HYPERPHOSPHATEMIA TREATMENT MARKET BY TEST TYPE

• 6.1. Introduction
• 6.2. Serum Phosphate Level Test
• 6.3. Serum Calcium Level Test
• 6.4. Blood Urea Nitrogen (BUN) Test
• 6.5. Serum Creatinine Test
• 6.6. Others

7. HYPERPHOSPHATEMIA TREATMENT MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Retail Pharmacies
• 7.4. Online Pharmacies

8. HYPERPHOSPHATEMIA TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Product
  • 8.3.2. By Test Type
  • 8.3.3. By Distribution Channel
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Product
  • 8.4.2. By Test Type
  • 8.4.3. By Distribution Channel
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Product
  • 8.5.2. By Test Type
  • 8.5.3. By Distribution Channel
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Product
  • 8.6.2. By Test Type
  • 8.6.3. By Distribution Channel
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Taiwan
    • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Ardelyx, Inc.
• 10.2. Kissei Pharmaceutical Co., Ltd.
• 10.3. Astellas Pharma Inc.
• 10.4. Chugai Pharmaceutical Co., Ltd.
• 10.5. Sanofi S.A.
• 10.6. Akebia Therapeutics, Inc.
• 10.7. Fresenius Medical Care AG & Co. KGaA
• 10.8. Vifor Pharma AG

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations